Long-term survivors in metastatic non-small-cell lung cancer: an Eastern Cooperative Oncology Group Study.
about
Optimizing the management of advanced non-small-cell lung cancer: a personal viewHematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCTPrognostic models to predict survival in non-small-cell lung cancer patients treated with first-line paclitaxel and carboplatin with or without bevacizumabA laboratory prognostic index model for patients with advanced non-small cell lung cancerPack-years of cigarette smoking as a prognostic factor in patients with stage IIIB/IV nonsmall cell lung cancer.[A meta-analysis of pemetrexed plus platinum chemotherapy versus gemcitabine plus platinum chemotherapy for advanced non-small cell lung cancer].Prospective study on the incidence of bone metastasis (BM) and skeletal-related events (SREs) in patients (pts) with stage IIIB and IV lung cancer-CSP-HOR 13.Innovative treatments for non-small cell lung cancer.Smoking and prognostic factors in an observational setting in patients with advanced non-small cell lung carcinomaSpecific organ metastases and survival in metastatic non-small-cell lung cancer.Eligibility for bevacizumab as an independent prognostic factor for patients with advanced non-squamous non-small cell lung cancer: a retrospective cohort study.Radiotherapy Planning Complexity and Survival after Treatment of Advanced Stage Lung Cancer in the ElderlyGlasgow prognostic score in patients receiving chemotherapy for non-small-cell lung cancer in stages IIIb and IV.Lung cancer--where are we today? Current advances in staging and nonsurgical treatment.Controversies in the nonsurgical treatment of stage III non-small cell lung cancer.Clinical analysis of 50 Eastern Asian patients with primary pulmonary large-cell neuroendocrine carcinoma.Prognostic Factors in Advanced Non-Small-Cell Lung Cancer Patients: Patient Characteristics and Type of Chemotherapy.A new scoring system for predicting survival in patients with non-small cell lung cancerPerformance and prognosis in patients with lung cancer. The Edinburgh Lung Cancer Group.Differential effect of age on survival in advanced NSCLC in women versus men: analysis of recent Eastern Cooperative Oncology Group (ECOG) studies, with and without bevacizumabIs Human Kallikrein 11 in Non-small Cell Lung Cancer Treated Chemoradiotherapy Associated with Survival?Stage IV EGFR Mutation-Negative and ALK Mutation-Negative Lung Adenocarcinoma: Long-Term Survival is Possible.Differences in the survival of patients with recurrent versus de novo metastatic KRAS-mutant and EGFR-mutant lung adenocarcinomas.Erlotinib in salvage treatment of patients with advanced non-small cell lung cancer: results of an expanded access programme in Poland.A prognostic model for platinum-doublet as second-line chemotherapy in advanced non-small-cell lung cancer patients.Determinants of survival in advanced non--small-cell lung cancer in the era of targeted therapiesGermline genetic variations in drug action pathways predict clinical outcomes in advanced lung cancer treated with platinum-based chemotherapyOutcomes of patients with unresected stage III and stage IV non-small cell lung cancer: A single institution experience.Age is a prognostic factor affecting survival in lung cancer patients.Genetic variants of CHRNA5-A3 and CHRNB3-A6 predict survival of patients with advanced non-small cell lung cancer.Phase II study of docetaxel and celecoxib, a cyclooxygenase-2 inhibitor, in elderly or poor performance status (PS2) patients with advanced non-small cell lung cancer.Nutritional status in the era of target therapy: poor nutrition is a prognostic factor in non-small cell lung cancer with activating epidermal growth factor receptor mutationsCombination chemotherapy of gemcitabine and vinorelbine for pretreated non-small-cell lung cancer: a retrospective study.The effect of the gastrectomy on survival in patients with metastatic gastric cancer: a study of ASMO.Relationship between efficacy outcomes and weight gain during treatment of advanced, non-squamous, non-small-cell lung cancer patients.[Clinical investigation of efficacy of pemetrexed in 32 patients with pulmonary adenocarcinoma after failure to chemotherapy and gefitinib].Elevated pretreatment serum concentration of YKL-40-An independent prognostic biomarker for poor survival in patients with metastatic nonsmall cell lung cancer.Outcomes among African-American/non-African-American patients with advanced non-small-cell lung carcinoma: report from the Cancer and Leukemia Group B.Steroid-hormone receptors in cell lines and tumor biopsies of human lung cancer.Reliability of X-rays and bone scans for the assessment of changes in skeletal metastases from breast cancer.
P2860
Q24656144-93B98F06-C0F4-45D1-918C-A240D503277BQ24685958-7754F8BD-4168-4033-A497-AFDB12F8870CQ28388270-D054BBAD-63C2-4931-B08B-CCED6D3A2026Q28542513-4D0EC844-FC62-4FD8-991B-9360B16F1D05Q33625469-632265DB-777F-4FB7-B4BE-10F9614DDA73Q33789669-BC784F6D-CF44-4325-94D2-FB27136CA05EQ34041808-416A50DE-8A2E-4335-8AE5-8ED64F84B296Q34481453-0FC9F070-DFC9-4A0E-BCCD-B40B3E2B7468Q34487100-1B1AFC7B-F45C-4511-A4C2-7305BC5AD7A9Q34607284-6817FF77-1893-48BA-9BA1-FDC95D40D4B9Q34651916-AA02E85A-0E28-4C98-ADEF-122469749F9FQ34680500-E9385D4F-16DA-4D14-9285-FCD01A61EBC6Q34746166-62DAE5DB-DF37-45E1-9CA4-B102C09B82D1Q34982142-4ADFEE60-CF7B-453F-94F9-FF936CE7BE40Q35226646-1544F8B6-19E8-4ED1-A74F-A35E19A9B519Q35679386-99E4D444-C171-45A4-B74E-AC9317C379F9Q35763231-E4368D6F-221B-4BDD-ABCE-000DF8B06FADQ36051766-71C9A61A-34D3-4CB9-9FF5-D0A960BD3AB4Q36235429-483D392F-F7EA-4DC6-A2D8-81ED5765AC0AQ36286698-B053E756-66D2-44C8-A591-C639292F709EQ36482606-D7A58822-AF21-4C41-95BF-DC578920F79CQ36499068-FB44195C-940B-4431-ADC2-789892EBE301Q36666814-331E82E0-FD58-4B6C-BA05-677D57045D3BQ36942514-335B1609-F650-41CD-945D-4943D1338524Q37045552-6E0A81F8-81DA-4E60-82F5-91CC6423F672Q37146779-8E43B2C1-60D1-4D98-A210-A8163A882BCAQ37150706-555130C2-5192-4542-8C1F-6A559FD4373FQ37177238-9A174183-F57C-4ED6-9B60-FD1A2FB62538Q37269229-5973C4EE-6129-4523-83DE-A35B3171C09CQ37295691-DF64D2C9-6BB9-47FB-B770-5568207E9B3BQ37383735-AC8B773D-F3A5-4EFF-9685-C671F2C9E1DAQ37392446-E470A223-E55F-414D-BBAC-FC8E90915F88Q37566846-8022CF80-64FE-4EA3-8FB7-3A95C751BEACQ38919830-6FECB93B-5FA4-4DBA-A8A9-D6B52FBB0D4AQ39741230-DE55AD15-0754-4955-828D-981CCBB17A15Q42939496-8D635B53-A474-42EE-9497-FE7FA08EDBA6Q43011817-CEF81469-5A68-4FD6-979B-252BA3CC27DAQ46670739-F1DDC5DA-30CA-4554-BE61-E612183FF9BEQ51023039-4099C64B-47EE-4AF3-95BE-B56321165B93Q52969921-CFE8E56D-892E-44E3-ADFF-52B4856E8BB3
P2860
Long-term survivors in metastatic non-small-cell lung cancer: an Eastern Cooperative Oncology Group Study.
description
1986 nî lūn-bûn
@nan
1986年の論文
@ja
1986年論文
@yue
1986年論文
@zh-hant
1986年論文
@zh-hk
1986年論文
@zh-mo
1986年論文
@zh-tw
1986年论文
@wuu
1986年论文
@zh
1986年论文
@zh-cn
name
Long-term survivors in metasta ...... perative Oncology Group Study.
@en
Long-term survivors in metasta ...... perative Oncology Group Study.
@nl
type
label
Long-term survivors in metasta ...... perative Oncology Group Study.
@en
Long-term survivors in metasta ...... perative Oncology Group Study.
@nl
prefLabel
Long-term survivors in metasta ...... perative Oncology Group Study.
@en
Long-term survivors in metasta ...... perative Oncology Group Study.
@nl
P356
P1476
Long-term survivors in metasta ...... perative Oncology Group Study.
@en
P2093
D M Finkelstein
D S Ettinger
P304
P356
10.1200/JCO.1986.4.5.702
P407
P577
1986-05-01T00:00:00Z